stockrowVaxcyte, Inc.
PCVX Healthcare Biotechnology
- EPS
- −61.5%
- Free cash flow
- −92.6%
Quarter to June 2026, against a year earlier
Follow PCVX
Alert me
Vaxcyte, Inc. (PCVX) Return on assets
Vaxcyte, Inc.'s return on assets over the twelve months to 30 June 2026 was −33.0%, down 9.5 percentage points from fiscal 2025 (−23.5%). Over the past ten years it has ranged from −83.3% (fiscal 2018) to −18.9% (fiscal 2024); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −23.5% | (4.68) |
| FY2024 | −18.9% | 14.47 |
| FY2023 | −33.3% | 0.26 |
| FY2022 | −33.6% | (5.68) |
| FY2021 | −27.9% | 11.00 |
| FY2020 | −38.9% | 34.75 |
| FY2019 | −73.7% | 9.63 |
| FY2018 | −83.3% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 37.7% |
| PTGX Protagonist Therapeutics, Inc. compare | 10.3% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| TECH Bio-Techne Corp compare | 7.07% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.20% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.1% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| PCVX Vaxcyte, Inc. | −33.0% |
| IBRX ImmunityBio, Inc. compare | −192.6% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)